Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Salbutamol sulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for should be ensured that, wherever possible, Salamol Easi-Breathe® is 2. What you need to know before you use Salamol Easi-Breathe® • have phaeochromocytoma (a certain disease of the adrenal medulla – the inner part of the adrenal gland). no longer used for at least 6 hours before the start of anaesthesia. 3. How to use Salamol Easi-Breathe® 4. Possible side effects Your inhaler does not have a dose counter. Your inhaler contains The blood sugar level can rise if Salamol Easi-Breathe® is inhaled 5. How to store Salamol Easi-Breathe® enough medicine for 200 puffs only (whether inhaled and/or at high doses. In patients with diabetes, blood sugar levels 6. Contents of the pack and other information released into the air for testing) and it contains a propellant gas should be closely monitored. 1. What Salamol Easi-Breathe® is and what it is to deliver the medicine. However, after 200 puffs, your inhaler Hypokalaemia (a reduction in blood potassium levels) may occur can continue to spray the gas but without the right dose of during high-dose treatment with Salamol Easi-Breathe®. This can used for salbutamol, so you cannot be sure you will receive any medicine be made even worse if used at the same time as other Effect after using 200 puffs. Methods of telling that the inhaler is especially methylxanthines (e.g. theophylline), Salamol Easi-Breathe® contains salbutamol sulfate, which belongs empty like shaking it, weighing it, or floating it in water, are not medicines, corticosteroids (cortisone-like medicines), diuretics (used to to a group of medicines called beta agonists. Salbutamol is a reliable. You should consider recording the number of puffs used. increase urine output) or digitalis glycosides (medicines used to bronchodilator and works by widening the airways in your lungs to You could also consider keeping a back-up inhaler. If you are heart failure), or if you also have hypoxaemia (low blood allow air in and out. This helps you to feel less breathless, wheezy using more than one inhaler, it is recommended to keep track of treat oxygen levels). Blood electrolyte monitoring is indicated, so that or tight-chested. the number of puffs used for each inhaler separately. potassium can be administered if necessary. Usage Special treatment instructions As with other inhaled treatments, a bronchial spasm (paradoxical Salamol Easi-Breathe® is used to treat asthma in adults, Treatment of asthma should follow a stepwise approach in bronchospasm) may occur after using Salamol Easi-Breathe®, with adolescents and children aged 4 to 11 years. It can also be used accordance with disease severity. an immediate increase in wheezing. In this case, a fast-acting to prevent asthma caused by exercise or asthma caused by a may be dangerous for patients to increase the use of bronchodilator should be inhaled immediately. Treatment with reaction to allergens (substances to which you are allergic to e.g. It Easi-Breathe® should be stopped at once and the treating house dust, pollen, dog hair, cat hair, cigarette smoke, etc.) or to beta2-agonists, such as Salamol Easi-Breathe®, of their own accord. Salamol If your breathlessness should suddenly get worse after inhalation doctor should be informed. He/she will decide whether further treat breathing difficulties associated with reversible airways measures are required. obstruction (e.g. chronic obstructive pulmonary disease [COPD]). (paradoxical bronchospasm), treatment should be discontinued Children This type of medicine is known as a 'reliever'. You may be using immediately and your treatment plan revised by the doctor. another medicine to prevent you from having an asthma attack Salbutamol should not be used as monotherapy in patients with The specific dosage recommendations for children aged 4 to 11 years should be observed (see section 3). persistent asthma. ("controller medication"). You can safely use your controller Elderly medication with this medicine. An increasing need for beta2-agonists, such as Salamol No special dosage adjustment is required in the elderly. In asthma, fast-acting bronchodilators including Salamol Inhaler Easi-Breathe®, is a sign of worsening disease. Other medicines and Salamol Easi-Breathe® should not be the main or only treatment. It is recommended that If, despite treatment, there is no satisfactory improvement or Tell your doctor or pharmacist if you are taking/using, have Salamol Inhaler should always be prescribed with an inhaled even worsening of the disease, the treatment plan must be corticosteroid (anti-inflammatory) medicine. reviewed by the doctor and, if necessary, reworked by combining recently taken/used or might take/use any other medicines. it with anti-inflammatories, adjusting the dose of pre-existing If you are having treatment that requires a general anaesthetic,
e anti-inflammatory therapy or co-administering other medicines. If please tell your anaesthetist that you are taking Salamol Salamol Easi-Breathe® breathlessness should develop suddenly or rapidly get worse, Easi-Breathe®. Do not use this medicine for at least six hours Do not use Salamol Easi-Breathe® you must seek medical help at once. before the intended anaesthetic.
Antidiabetic agents (used to treat diabetes) The blood sugar-lowering effect of antidiabetics can be reduced during treatment with Salamol Easi-Breathe®. However, this is generally only to be expected at higher doses that are usual in systemic administration (as tablets or injection/infusion). Digitalis glycosides (cardiac glycosides) and antiarrhythmic agents An increased risk of side effects is possible if Salamol Easi-Breathe® is given at the same time as antiarrhythmic agents (e.g. digitalis/quinidine). Anaesthetics The use of halogenated anaesthetics (used in general anaesthesia), such as halothane, methoxyflurane or enflurane, must be expected to increase the risk of severe heart rhythm disorders and hypotension (reduction in blood pressure) in patients treated with Salamol Easi-Breathe® (see 2. 'What you need to know before you use Salamol Easi-Breathe®'). Sympathomimetics (medicines that act on the autonomic nervous system) If given at the same time, Salamol Easi-Breathe® and theophylline or other sympathomimetics may mutually enhance their respective effects, with an increased risk of side effects. In addition, substances which themselves enhance sympathomimetic effects, such as L dopa, L thyroxine, oxytocin or alcohol, can have an effect on cardiovascular regulation in interaction with Salamol Easi-Breathe®. Hypokalaemia (reduction in blood potassium levels) possibly triggered by Salamol Easi-Breathe® can be made even worse if you are also taking methylxanthines (e.g. theophylline), corticosteroids, diuretics or digitalis glycosides. Caution is required if you are being treated with ergot alkaloid-type substances, such as ergotamine, at the same time as Salamol Easi-Breathe®, as the mutual effect on the vasomotor system (vasodilatory regulation) is difficult to predict individually and may also lead to vasoconstrictor and vasodilator reactions (narrowing or widening of the blood vessels). If used at the same time, Salamol Easi-Breathe® and monoamine oxidase inhibitors or tricyclic antidepressants can trigger an increased effect of salbutamol on the cardiovascular system. Hypertensive reactions, causing a rise in blood pressure, may occur if procarbazine is given at the same time. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Salbutamol crosses the placental barrier. For humans, there is insufficient experience with regard to use during pregnancy. An increase in heart rate (tachycardia) and low blood sugar levels (hypoglycaemia) have been described in newborns with the use of salbutamol as a tocolytic agent. Animal studies have shown reproductive toxicity in rats at very high doses. The potential risk for humans is unknown.
Salamol Easi-Breathe® should not be used during pregnancy, especially during the first three months, unless strictly indicated. The same applies to its use at the end of pregnancy, due to the tocolytic effect, which delays labour. As salbutamol probably passes into human milk, its use during breast-feeding is recommended only after a careful risk/benefit assessment. Driving and using machines No studies have been carried out on the effects on the ability to drive and operate machinery. Salamol Easi-Breathe® contains ethanol This medicine contains 3.93 mg of alcohol (ethanol) in each metered dose. The amount in each metered dose of this medicine is equivalent to less than 0.1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects.
Salamol Easi-Breathe® Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The dosage is individually adjusted according to your doctor's instructions, based on previous asthma therapy. For the best results with this medicine you should use it when required to relieve symptoms of asthma and other chest conditions with similar symptoms, such as wheezing, breathlessness and tightness in your chest. Take one puff as a starting dose. This may be increased to two puffs if necessary. To prevent asthma caused by exercise or allergens (e.g. house dust, pollen etc.), take two puffs 10-15 minutes before you exercise or before exposure to known allergens. Do not take more than eight puffs in 24 hours. Wait 4 hours between doses. Salamol Easi-Breathe® should be used as required rather than regularly. If your asthma is active (for example you have frequent symptoms or flare ups, such as breathlessness that makes speaking, eating or sleeping difficult, cough, wheezing, tight chest or limited physical ability), you should tell your doctor right away who may start or increase a medicine to control your asthma such as an inhaled corticosteroid. Tell your doctor as soon as possible if your medicine does not seem to be working as well as usual (for example you need higher doses to relieve your breathing problems or your inhaler fails to give relief for at least 3 hours) as your asthma may be getting worse and you may need a different medicine. If you use Salamol Easi-Breathe® more than twice a week to treat your asthma symptoms, not including preventive use before exercise, this indicates poorly controlled asthma and may increase the risk of severe asthma attacks (worsening of asthma) that can have serious complications and may be life-threatening or even fatal. You should contact your doctor as soon as possible to review your asthma treatment.
If you use a medicine against inflammation of your lungs daily, Closed Open e.g., "inhaled corticosteroid", it is important to continue using it regularly, even if you feel better. Air Holes Use in children and adolescents Top The usual dose for children under the age of 12 years to relieve asthma symptoms such as wheezing, breathlessness and tightness in the chest, is one puff as a starting dose. This may be Cap increased to two puffs if necessary. Children over the age of 12 should refer to the adult dosage instructions above. The usual dose for children under the age of 12 years to prevent asthma caused by exercise or allergens (e.g. house dust, pollen etc.), is one puff 10-15 minutes before exercise or before exposure to known allergens. This can be increased to two puffs if necessary. Children over the age of 12 should refer to the adult dosage instructions above. The usual dose for children under the age of 12 years for regular treatment of asthma (along with regular asthma anti-inflammatory medicine – inhaled corticosteroid) is up to 2 puffs, 4 times a day. Test spray the inhaler by firing two shots into the air before you use it for the first time and also if you have not used it for a Do not take more than eight puffs in 24 hours. Wait 4 hours period of five days or more. To test spray your inhaler, unscrew between doses. the top of it so you can see the metal can inside. Open the cap, Instructions for use shake the inhaler and spray the aerosol by The inhaler does not have a dose counter, you can consider pressing the can with your finger or thumb. recording the number of puffs you are taking. If you are using Close the cap and put the top back on. more than one inhaler, it is recommended to keep track of the 1 1. Shake the inhaler vigorously. number of doses for each inhaler separately. 2. Hold the inhaler upright and open it by Important folding down the cap which fits over the Before using this medicine, please read this leaflet carefully and mouthpiece. follow the instructions. 3. Breathe out normally as far as you An adult should always supervise children when they use comfortably can. Then hold the Salamol Easi-Breathe®. mouthpiece firmly between your lips. Always remember the following: Hold the inhaler upright and make sure
It is important to clean your inhaler regularly 4 to prevent deposits from the aerosol building up and blocking the inhaler. If your inhaler does not seem to be working, it may be that your inhaler has become blocked and you should clean your inhaler as detailed below. If your inhaler still does not work, return it to your doctor or pharmacist. Cleaning the inhaler You must keep your inhaler clean, especially in the mouthpiece. This will prevent deposits from the aerosol building up. To prevent your inhaler becoming blocked you must clean it once a week. A To clean your inhaler unscrew and remove A the top of the inhaler. Keep this top dry at all times.
B Remove the metal can from the bottom of the inhaler. Do not put the metal can into water.
B
C Rinse the bottom of the inhaler with warm running water for at least 30 seconds.
C
D Shake off any excess water and dry the bottom of the inhaler thoroughly (leave to dry overnight if possible) but do not use direct heat. Put the can back into the bottom of the inhaler. Close the cap and screw the top and bottom parts of your inhaler back together.
D
Failure to allow the mouthpiece to dry properly will result in an increase in blockage problems.
happens, you may notice an irregular heartbeat, muscle If you need to use your inhaler before it is dry, shake off any weakness or cramp) water from the bottom of the inhaler and put the can back in. Test spray the inhaler by firing two puffs in the air as previously • Increase in lactate levels and acid levels in the blood (you may experience symptoms such as persistent nausea and described above. Screw the top and bottom parts of your inhaler vomiting, unexplained tiredness, shortness of breath and together and take your usual dose. When you have taken your rapid breathing, cold or blue hands and feet) usual dose, wash and dry your inhaler again as described above.
(ventricular extrasystoles) and chest tightness (anginal complaints). Like all medicines, this medicine can cause side effects, although
Salamol Easi-Breathe®
no longer use. These measures will help protect the environment.
What Salamol Easi-Breathe® contains
292112_s1
Salamol Easi-Breathe CFC-Free Inhaler comes as inhaler. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Salamol Easi-Breathe CFC-Free Inhaler is salbutamol sulfate.
This leaflet reproduces the patient information leaflet approved for Salamol Easi-Breathe CFC-Free Inhaler, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
The symptomatic treatment of asthma and other conditions with associated reversible airways obstruction. For relief of wheezing and shortness of breath, Salamol Easi-Breathe CFC-Free Inhaler should be used on an 'as required' basis.
Prevention of asthma attacks induced by exercise or exposure to allergens.
In asthma, short acting beta-2 agonists including Salamol CFC-Free Inhaler should not be the main or only treatment. It is recommended that short acting beta-2 agonists should be prescribed with concomitant inhaled corticosteroid (anti-inflammatory).
Salamol Easi-Breathe CFC-Free Inhaler is indicated in adults, adolescents and children aged 4 to 11 years. For infants and children under 4 years of age, see section 5.1.
Posology
For optimum results in most patients Salamol Easi-Breathe CFC-Free Inhaler should be used as required.
Adults (including the elderly)
Relief of acute asthma symptoms including bronchospasm
One inhalation (100 micrograms) may be administered as a single minimum starting dose. This may be increased to two inhalations (200 micrograms) if necessary.
Prevention of allergen or exercise-induced bronchospasm
Two inhalations (200 micrograms) should be taken 10-15 minutes before challenge.
On demand use of Salamol Easi-Breathe CFC-Free Inhaler should not exceed 8 inhalations (800 micrograms) in any 24 hours. Inhalations should not usually be repeated more often than every 4 hours. Reliance on such frequent supplementary use, or a sudden increase in dose indicates poorly controlled or deteriorating asthma.
For all patients, four hours should be allowed between each dose.
Paediatric population
Relief of acute asthma symptoms including bronchospasm
The usual dosage for children under the age of 12 years: one inhalation (100 micrograms). The dose may be increased to two inhalations (200 micrograms) if required.
Children aged 12 years and over: Dose as per adult population.
Prevention of allergen or exercise-induced bronchospasm
The usual dosage for children under the age of 12 years: one inhalation (100 micrograms) before challenge or exertion. The dose may be increased to two inhalations (200 micrograms) if required.
Children aged 12 years and over: Dose as per adult population.
The usual dosage for children under the age of 12 years: up to two inhalations 4 times daily.
Children aged 12 years and over: Dose as per adult population.
Patients with Hepatic or Renal Impairment
No need to adjust the dose.
Method of administration
Inhalation use.
Salamol Easi-Breathe® administration in children should be supervised by an adult. Patients should wait four hours between doses.
Patients should sit, or stand, upright during inhalation. It is also important that the inhaler should be held in an upright position, as the inhaler works correctly only in a vertical position.
The aerosol spray is inhaled through the mouth into the lungs. The inhaler should be tested by spraying the inhaler by firing two shots into the air before first use, and if the inhaler has not been used for a period of five days or longer.
Use of the inhaler
1. Patients should shake the inhaler vigorously.
2. The inhaler must be held upright. Patients should open it by folding down the cap which fits over the mouthpiece.
3. Patients should exhale normally, and place the mouthpiece in their mouth with their lips closed around it. They should hold the inhaler upright and make sure that their hand is not blocking the airholes. Inhalation through the mouthpiece should be slow and deep. Patients should be advised not to stop breathing when the inhaler puffs the dose into their mouth. After that, they should carry on until they have taken a deep breath.
4. Patients should remove the inhaler from their mouth and hold their breath for 10 seconds or as long as they comfortably can. Then, exhale slowly.
5. After using the inhaler, patients should hold it upright and close the cap immediately.
6. If more than one puff is needed, patients should close the cap, wait about one minute and then start again from step 1.
Patients should be advised to clean the inhaler once a week, especially in the mouthpiece to prevent deposits from the aerosol building up.
As with most inhaled medicinal products in pressurised containers, the therapeutic effect of this medicinal product may decrease when the container is cold.
The container should not be punctured, broken or burnt, even when apparently empty.
The metal container must not be put into water.
Full instructions for use are given in the Patient Information Leaflet which should be read carefully by the patient before use.
Cleaning of the inhaler
Patients must clean the inhaler once a week.
A Unscrew and remove the top of the inhaler. Patients should be advised to keep this top dry all the time.
B Remove the metal from the bottom of the inhaler. Patients should be advised not to put the container into water
C Rinse the bottom of the inhaler with warm running water for at least 30 seconds
D Shake off any excess water and dry the bottom of the inhaler thoroughly (overnight if possible). It is important to advise patients not to use direct heat. Patients should put the can back into the bottom of the inhaler. Then, close the cap and screw the top and bottom parts of their inhaler back together.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Salbutamol inhalation is contraindicated in treatment of threatened abortion or premature labour.
Salbutamol should be used with caution and only when strictly indicated in the following cases:
• hypersensitivity to other sympathomimetics
• hyperthyroidism/thyrotoxicosis
• coronary insufficiency
• hypertrophic obstructive cardiomyopathy
• recent heart attack
• severe and untreated arterial hypertension
• tachycardia and known tachyarrhythmias
• Phaeochromocytoma
• Aneurysms
• concomitant use of cardiac glycosides
• difficult-to-control diabetes mellitus.
Patients should be instructed in the proper use of the inhaler and their technique checked, to ensure that the active substance reaches the target areas within the lungs.
The inhaler contains enough salbutamol for a total of 200 actuations (puffs). After the 200 actuations (puffs) have been used, the inhaler can when actuated continue to release a spray of propellant which no longer contains the prescribed dose of salbutamol. Methods such as shaking, weighing or submerging inhalers are not accurate for determining that an inhaler is empty of the prescribed dose of salbutamol. To avoid inadvertent use of an empty inhaler, maintaining a record of the number of actuations (puffs) administered to the patient should be considered. Keeping a back-up inhaler could also be considered. If the patient has more than one inhaler, it is recommended to keep track of doses administrated from each inhaler separately (see section 6.6).
The management of asthma should normally follow a stepwise programme, and the patient's response should be monitored clinically and by lung function tests.
Patients who are prescribed regular anti-inflammatory therapy (e.g., inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms decrease, and they do not require Salamol Easi-Breathe CFC-Free Inhaler.
Increasing use of short-acting inhaled bronchodilators, in particular ß2-agonists to control symptoms, indicates deterioration of asthma control, and patients should be warned to seek medical advice as soon as possible. If, despite therapy, there is no satisfactory improvement or even exacerbation of the disease, the treatment plan must be reviewed by the physician and, if necessary, reformulated by combining it with anti-inflammatories, adjusting the dose of pre-existing anti-inflammatory therapy or co-administering other medicinal products.
Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.
Patients who take more than twice a week “as needed” salbutamol, not counting prophylactic use prior to exercise, should be re-evaluated (i.e., daytime symptoms, night- time awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of salbutamol.
Salbutamol should not be used as monotherapy in patients with persistent asthma.
The dosage or frequency of administration should only be increased on medical advice.
Patients requiring long term management with Salamol Easi-Breathe CFC-Free Inhaler should be kept under regular surveillance.
Care should be taken when treating acute asthma attacks or exacerbation of severe asthma as increased serum lactate levels, and rarely, lactic acidosis have been reported after the use of high doses of salbutamol have been used in emergency situations this is reversible on reducing the dose of salbutamol
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmias or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be either respiratory or cardiac in origin.
Potentially serious hypokalaemia may result from ß2-agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.
Significantly exceeding the recommended doses (in particular the single doses used in an acute attack, but also the total daily dose) can be dangerous because of possible cardiac side effects, especially in association with electrolyte imbalances (e.g., hypokalaemia), and must therefore be avoided.
As with other beta-adrenoceptor agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Diabetic patients may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported. Concurrent administration of glucocorticoids can exaggerate this effect.
If treatment with Salamol Easi-Breathe CFC-Free Inhaler is initiated in diabetics, additional blood glucose monitoring is recommended as beta2-agonists increase the risk of hyperglycaemia.As with other inhalation therapies, the potential for paradoxical bronchospasm with immediate exacerbation of wheezing should be considered. If it occurs the preparation should be discontinued immediately and alternative therapy given. In such cases, treatment should be switched immediately to a different dosage form or to another fast-acting inhaled bronchodilator.
Solutions which are not of neutral pH may rarely cause paradoxical bronchospasm in some patients. Salbutamol and non-selective beta blocking drugs such as propranolol should not usually be prescribed together.
Excipient(s)
Ethanol
This medicine contains 3.93 mg of alcohol (ethanol) in each metered dose. The amount in each metered dose of this medicine is equivalent to less than 0.1 ml beer or wine.
The small amount of alcohol in this medicine will not have any noticeable effects.
Concomitant use of salbutamol and beta-receptor antagonists leads to a mutual attenuation of effect, whereby the administration of beta-receptor antagonists in patients with bronchial asthma carries the risk of triggering severe bronchospasm.
Furthermore, the hypoglycaemic effect of antidiabetics can be reduced during treatment with salbutamol. However, this is generally only to be expected at higher doses that are usual in systemic administration (as tablets or injection/infusion).
Mutual potentiation of the effects and an increased risk of adverse reactions are possible if salbutamol is co-administered with theophylline (and theophylline derivatives) or other sympathomimetics.
An increased risk of adverse reactions is possible if salbutamol is co-administered with antiarrhythmic agents (e.g. digitalis glycosides/quinidine).
In addition, substances which themselves potentiate sympathomimetic effects, such as L dopa, L thyroxine, oxytocin or alcohol, can have an effect on cardiovascular regulation in interaction with salbutamol.
Concomitant treatment of salbutamol and substances of the ergot alkaloid type, such as ergotamine, should be carried out only with caution, since the reciprocal influence on vasomotor activity is difficult to predict on an individual basis and can lead to vasoconstrictor as well as vasodilator reactions.
Concomitant use of salbutamol and monoamine oxidase inhibitors or tricyclic antidepressants can induce an increased effect of salbutamol on the cardiovascular system.
Hypertensive reactions may occur if procarbazine is co-administered.
The use of halogenated anaesthetics, such as halothane, methoxyflurane or enflurane, must be expected to increase the risk of severe cardiac arrhythmias and hypotension in patients treated with salbutamol (see Notes).
Notes:
When anaesthesia using halogenated anaesthetics is scheduled, it should be ensured that, wherever possible, salbutamol is no longer used for at least 6 hours before the start of anaesthesia.
Hypokalaemia may occur during high-dose therapy with salbutamol.
This can be further exacerbated with concomitant use of other medicinal products, especially methylxanthines (e.g. theophylline), corticosteroids, diuretics or digitalis glycosides, or if hypoxaemia is also present. Blood electrolyte monitoring is indicated, so that potassium can be administered if necessary.
Because of the content of ethanol, there is theoretical potential for interaction in patients taking disulfiram or metronidazole
Pregnancy
Salbutamol crosses the placental barrier. For humans, insufficient experience is available on use during pregnancy. Animal studies have shown reproductive toxicity at high doses (see section 5.3). The potential risk to humans is not known.
Salamol Easi-Breathe CFC-Free Inhaler during pregnancy should only be used in situations where the expected benefit to the mother is thought to outweigh any risk to the foetus.
Salamol Easi-Breathe CFC-Free Inhaler should be used during pregnancy, especially during the first three months, only in situations where the expected benefit to the mother is expected to outweigh any risk to the foetus. The same applies to use at the end of pregnancy because of the labour-inhibiting effect.
Salamol Easi-Breathe CFC-Free Inhaler
There is no documented evidence of the use of salbutamol formulated with propellant HFA- 134a in pregnant women.
Propellant HFA-134a
There is no documented evidence of the use of propellant HFA-134a in pregnant women. Pregnant animals exposed to high levels of HFA-134a showed no evidence of any adverse effects.
Salbutamol
Experience on the use of beta-sympathomimetics during early pregnancy indicates no harmful effect at the doses ordinarily used for inhalation therapy. High systemic doses at the end of pregnancy can cause inhibition of labour and may induce β2-specific foetal/neonatal effects like tachycardia and hypoglycaemia. Inhalation therapy at recommended doses is not expected to induce these harmful side effects at the end of pregnancy.
Breast-feeding
Salamol Easi-Breathe CFC-Free Inhaler should only be used in lactation in situations where the expected benefit to the mother is thought to outweigh any risk to the neonate.
Salamol Easi-Breathe CFC-Free Inhaler
There is no documented evidence of the use of salbutamol formulated with propellant HFA- 134a in lactating women.
Propellant HFA-134a
There is no documented evidence of the use of propellant HFA-134a in lactating women. Lactating animals exposed to high levels of HFA-134a showed no evidence of any adverse effects.
Salbutamol
Salbutamol may be secreted in breast milk. It is not known whether salbutamol has a harmful effect on the neonate.
Fertility
There is no information on the effects of salbutamol on human fertility. In animals, there were no negative effects on fertility (see section 5.3).
No studies have been carried out on the effects on the ability to drive and operate machinery.
Based on the MedDRA system organ class and frequencies, adverse events are listed in the table below.
Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available data).
System Organ Class
Frequency
Adverse Event
Immune system disorders
Very rare
Hypersensitivity reactions (including angioedema, urticaria, exanthema bronchospasm, hypotension and collapse)
Metabolism and nutrition disorders
Common
Rare
Hyperglycaemia
Hypokalaemia*, increased serum lactate levels and acidosis lactic
Psychiatric disorders
Common
Rare
Very rare
Tenseness
Sleep disturbances and hallucinations (especially in children), hyperactivity in children
Insomnia
Nervous system disorders
Common
Uncommon
Tremor muscle, headache**, dizziness
Restlessness**
Cardiac disorders
Common
Uncommon
Very rare
Tachycardia
Palpitations, myocardial ischaemia (see section 4.4)
Cardiac arrhythmia including atrial fibrillation, supraventricular tachycardia and (ventricular) extrasystoles and anginal complaints – especially if used concomitantly with other β2- agonists
Vascular disorders
Rare
Peripheral vasodilatation
Respiratory, thoracic and mediastinal disorders
Uncommon
Very rare
Throat irritation
Paradoxical bronchospasm (with an immediate increase in wheezing after dosing)§
Gastrointestinal disorders
Uncommon
Rare
Mouth irritation, changes in the sense of taste
Nausea, vomiting, dry mouth, sore mouth
Skin and subcutaneous tissue disorders
Very rare
Pruritus
Musculoskeletal and connective tissue disorders
Uncommon
Very rare
Myalgia, muscle cramps
Fine tremor (particularly of hands)
* Very marked hypokalaemia may possibly occur during therapy with beta2-agonists.
** Mild tremor and restlessness, as well as headache and muscle spasms, may resolve over the course of 1 to 2 weeks with continued treatment.
§ As with other inhalation therapies, paradoxical bronchospasm may occur immediately after dosing. Salamol Easi-Breathe CFC-Free Inhaler should be discontinued immediately, the patient reassessed and treated immediately with another presentation or a different fast- acting inhaled bronchodilator.
Treatment with Salamol Easi-Breathe CFC-Free Inhaler must be discontinued without delay, the patient examined and, if necessary, another form of therapy instituted (see also section 4.4).
Rarely, micturition disorders, heartburn and increases or decreases in blood pressure can occur.
Paediatric population
There have been isolated reports of a stimulant effect on the central nervous system after inhalation of salbutamol, which manifested as hyperexcitability, conspicuous hyperactive behaviour, sleep disorders and hallucinations. These observations were mainly made (90%) in children and adolescents up to 12 years of age.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms of an overdose
In the event of an overdose, the above-mentioned adverse reactions appear very rapidly and possibly in exaggerated form.
Typical symptoms are:
Tachycardia, palpitations, arrhythmias, restlessness, sleep disorders, chest pain and severe tremor, especially of the hands, but also the entire body. Uncommonly, psychotic reactions have been observed after excessive salbutamol doses.
Gastrointestinal complaints, including nausea, can occur, especially after oral intoxication.
In the event of an overdose with salbutamol, there may be increased shifts of potassium into the intracellular space, resulting in hypokalaemia, as well as hyperglycaemia, hyperlipidaemia and hyperketonaemia.
Lactic acidosis has been reported with high therapeutic doses and overdoses of short-acting beta-agonists. Thus, monitoring of patients for the development of elevated serum lactate levels and subsequent metabolic acidosis may be indicated (particularly if tachypnoea persists or worsens despite resolution of other signs of bronchospasm, such as wheezing).
Therapeutic measures in the event of overdose
Treatment after a beta-agonist overdose is mainly symptomatic and should also take into account the additive effect from any previous treatment with other medicinal products that can cause hypokalaemia.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Salamol Easi-Breathe CFC-Free Inhaler. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.